SEATTLE–(BUSINESS WIRE)–Adaptive Biotechnologies® announced today that the U.S. Food and Drug Administration (FDA) has granted De Novo designation for the clonoSEQ® Assay to detect and monitor minimal residual disease (MRD) in patients with multiple myeloma (MM) and B-cell acute lymphoblastic leukemia (ALL) using DNA from a patient’s bone marrow sample. The clearance …
Tag Archives: Adaptive Biotechnologies
October, 2018
September, 2018
-
28 September
Study Shows that Measuring MRD Negativity Using Adaptive’s Next-Generation Sequencing Platform is a Major Predictive Indicator in Multiple Myeloma
SEATTLE–(BUSINESS WIRE)–Adaptive Biotechnologies today announced that Blood, the Journal of the American Society of Hematology (ASH), published online an analysis of patient samples from the Intergroupe Francophone du Myéloma (IFM) 2009 trial. The analysis confirms the value of minimal residual disease (MRD) as a prognostic indicator in multiple myeloma (MM) measured …
May, 2018
-
31 May
Adaptive and Sanofi Collaborate to Use Adaptive’s clonoSEQ Assay in Active and Future Isatuximab Multiple Myeloma Trials
SEATTLE–(BUSINESS WIRE)–Adaptive Biotechnologies, the leader in combining Next Generation Sequencing (NGS) and expert bioinformatics to profile T- and B-cell receptors of the adaptive immune system, announced today that it entered into an agreement with Sanofi to utilize Adaptive’s NGS-based clonoSEQ® Assay to assess minimal residual disease (MRD) status in response to …
November, 2017
-
7 November
Adaptive Collaborates with Amgen to Advance Development of the clonoSEQ Assay in Multiple Myeloma
SEATTLE–(BUSINESS WIRE)–Adaptive Biotechnologies, a leader in combining next-generation sequencing (NGS) and sophisticated bioinformatics to profile T- and B-cell receptors of the adaptive immune system, announces it has entered into a collaboration agreement with Amgen to utilize Adaptive’s NGS-based clonoSEQ Assay in the Phase 3 CANDOR study, sponsored by Amgen in …
July, 2017
-
26 July
Adaptive’s ImmunoSEQ Platform to be Used for Immunosequencing-Based Biomarker Discovery in NCI Trials
SEATTLE–(BUSINESS WIRE)–Adaptive Biotechnologies, a pioneer in combining next-generation sequencing and expert bioinformatics to profile T-cell and B-cell receptors (TCRs and BCRs) of the adaptive immune system, today announced a translational collaboration with the Cancer Therapy Evaluation Program (CTEP) of the National Cancer Institute (NCI), part of the National Institutes of …
June, 2017
-
21 June
Janssen to Utilize Adaptive’s NGS-Based clonoSEQ Assay to Measure MRD in Darzalex Multiple Myeloma Trials
SEATTLE–(BUSINESS WIRE)–Adaptive Biotechnologies, the leader in combining Next Generation Sequencing (NGS) and expert bioinformatics to profile T- and B-cell receptors of the adaptive immune system, announces it has partnered with Janssen Biotech, Inc. to utilize Adaptive’s NGS-based clonoSEQ Assay for measuring minimal residual disease (MRD) in patients with Multiple Myeloma …
January, 2016
-
8 January
Pfizer Enters Immuno-Oncology Collaboration with Adaptive Biotechnologies
NEW YORK & SEATTLE–(BUSINESS WIRE)–Pfizer Inc. (NYSE: PFE) and Adaptive Biotechnologies Corporation have entered into a translational research collaboration to leverage next generation sequencing of the adaptive immune system to advance Pfizer’s growing immuno-oncology franchise. Under the terms of the agreement, Pfizer and Adaptive will seek to combine drug development …
April, 2015
-
29 April
Study Finds Adaptive Biotechnologies’ Next-Generation Sequencing-Based Technology Can Detect Hodgkin Lymphoma Disease Recurrence
Adaptive Biotechnologies’ next-generation genetic diagnostic technology has demonstrated the potential to detect trace amounts of classical Hodgkin’s lymphoma (CHL) that remains in the body after treatment. Researchers at The University of Texas MD Anderson Cancer Center conducted a study showing that Adaptive Biotechnologies’ next-generation sequencing-based approach to identification and quantification …